Deerfield Management Company, L.P. (Series C) Allogene Therapeutics, Inc. Transaction History

Deerfield Management Company, L.P. (Series C)

  • $5.38 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024
BUY
$2.28 - $3.5 $64,225 - $98,591
28,169 New
28,169 $90,000
Q2 2019

Aug 14, 2019
SELL
$25.56 - $31.09 $8.35 Million - $10.2 Million
-326,797 Closed
0 $0
Q4 2018

Feb 14, 2019
BUY
$22.5 - $33.3 $7.35 Million - $10.9 Million
326,797 New
326,797 $8.8 Million

Others Institutions Holding ALLO

# of Institutions
162
Shares Held
134M
Call Options Held
59.4K
Put Options Held
113K
View Full List

About Allogene Therapeutics, Inc.

ALLO Quotes by TradingView
  • Ticker ALLO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 143,807,008
  • Market Cap $326M
  • Description
  • Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...
More about ALLO
Track This Portfolio

Track Deerfield Management Company, L.P. (Series C) Portfolio

Follow Deerfield Management Company, L.P. (Series C) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Deerfield Management Company, L.P. (Series C), based on Form 13F filings with the SEC.

News

Stay updated on Deerfield Management Company, L.P. (Series C) with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email